Maurane Riesen1, Victor Garcia2, Nicola Low3, Christian L Althaus4. 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. Electronic address: maurane.riesen@ispm.unibe.ch. 2. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Electronic address: vic-garcia@gmx.net. 3. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Electronic address: nicola.low@ispm.unibe.ch. 4. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Electronic address: christian.althaus@alumni.ethz.ch.
Abstract
BACKGROUND: Completed human papillomavirus (HPV) vaccination by age 16 years among women in Switzerland ranges from 17 to 75% across 26 cantons. The consequences of regional heterogeneity in vaccination coverage on transmission and prevalence of HPV-16 are unclear. METHODS: We developed a deterministic, population-based model that describes HPV-16 transmission among young adults within and between the 26 cantons of Switzerland. We parameterized the model using sexual behavior data from Switzerland and data from the Swiss National Vaccination Coverage Survey. First, we investigated the general consequences of heterogeneity in vaccination uptake between two sub-populations. We then compared the predicted prevalence of HPV-16 resulting from heterogeneous HPV vaccination uptake in all of Switzerland with homogeneous vaccination at an uptake that is identical to the national average (52%). RESULTS: In our baseline scenario, HPV-16 prevalence in women is 3.34% when vaccination is introduced and begins to diverge across cantons, ranging from 0.19 to 1.20% after 15 years of vaccination. After the same time period, overall prevalence of HPV-16 in Switzerland is only marginally higher (0.63%) with heterogeneous vaccination uptake than with homogeneous uptake (0.59%). Assuming inter-cantonal sexual mixing, cantons with low vaccination uptake benefit from a reduction in prevalence at the expense of cantons with high vaccination uptake. CONCLUSIONS: Regional variations in uptake diminish the overall effect of vaccination on HPV-16 prevalence in Switzerland, but the effect size is small. Cantonal efforts towards HPV-prevalence reduction by increasing vaccination uptake are impaired by cantons with low vaccination uptake. Although the expected impact on national prevalence would be relatively small, harmonization of cantonal vaccination programs would reduce inter-cantonal differences in HPV-16 prevalence.
BACKGROUND: Completed human papillomavirus (HPV) vaccination by age 16 years among women in Switzerland ranges from 17 to 75% across 26 cantons. The consequences of regional heterogeneity in vaccination coverage on transmission and prevalence of HPV-16 are unclear. METHODS: We developed a deterministic, population-based model that describes HPV-16 transmission among young adults within and between the 26 cantons of Switzerland. We parameterized the model using sexual behavior data from Switzerland and data from the Swiss National Vaccination Coverage Survey. First, we investigated the general consequences of heterogeneity in vaccination uptake between two sub-populations. We then compared the predicted prevalence of HPV-16 resulting from heterogeneous HPV vaccination uptake in all of Switzerland with homogeneous vaccination at an uptake that is identical to the national average (52%). RESULTS: In our baseline scenario, HPV-16 prevalence in women is 3.34% when vaccination is introduced and begins to diverge across cantons, ranging from 0.19 to 1.20% after 15 years of vaccination. After the same time period, overall prevalence of HPV-16 in Switzerland is only marginally higher (0.63%) with heterogeneous vaccination uptake than with homogeneous uptake (0.59%). Assuming inter-cantonal sexual mixing, cantons with low vaccination uptake benefit from a reduction in prevalence at the expense of cantons with high vaccination uptake. CONCLUSIONS: Regional variations in uptake diminish the overall effect of vaccination on HPV-16 prevalence in Switzerland, but the effect size is small. Cantonal efforts towards HPV-prevalence reduction by increasing vaccination uptake are impaired by cantons with low vaccination uptake. Although the expected impact on national prevalence would be relatively small, harmonization of cantonal vaccination programs would reduce inter-cantonal differences in HPV-16 prevalence.
Authors: Victoria O Olarewaju; Kristen Jafflin; Michael J Deml; Nejla Gültekin; Franco Muggli; Susanna Schärli; Catherine Gruillot; Andrea Kloetzer; Benedikt M Huber; Sonja Merten; Philip E Tarr Journal: Hum Vaccin Immunother Date: 2021-11-09 Impact factor: 3.452
Authors: Laura M Kiener; Corina L Schwendener; Kristen Jafflin; Audrey Meier; Noah Reber; Susanna Schärli Maurer; Franco Muggli; Nejla Gültekin; Benedikt M Huber; Sonja Merten; Michael J Deml; Philip E Tarr Journal: BMJ Open Date: 2022-04-21 Impact factor: 3.006
Authors: Emilien Jeannot; Manuella Viviano; Charlotte de Pree; Mona Amadane; Emmanuel Kabengele; Pierre Vassilakos; Patrick Petignat Journal: Int J Environ Res Public Health Date: 2018-07-09 Impact factor: 3.390
Authors: André B Kind; Andrew Pavelyev; Smita Kothari; Nadia El Mouaddin; Aurélie Schmidt; Edith Morais; Patrik Guggisberg; Florian Lienert Journal: BMC Public Health Date: 2020-05-12 Impact factor: 3.295